Debio 0932 is primarily investigated for its potential in cancer therapy. It functions as a heat shock protein 90 (HSP90) inhibitor, which plays a crucial role in stabilizing and activating various client proteins involved in cancer cell survival and proliferation. By inhibiting HSP90, Debio 0932 disrupts the function of these client proteins, leading to the degradation of oncogenic proteins and inhibition of tumor growth. It has been explored in preclinical and clinical studies for its efficacy in treating various cancers, including lung cancer and other solid tumors. The compound is particularly noted for its ability to enhance the effects of other cancer therapies, making it a promising candidate for combination treatments. Ongoing research aims to further understand its therapeutic potential and optimize its use in clinical settings.